Breaking News Instant updates and real-time market news.

AXGN

AxoGen

$20.44

-1.74 (-7.84%)

06:23
03/25/19
03/25
06:23
03/25/19
06:23

AxoGen upgraded to Buy from Neutral at BTIG

BTIG analyst Ryan Zimmerman upgraded AxoGen to Buy with a price target of $28, citing the stabilizing of its sales force based on his analysis of LinkedIn data and expectations that the management will have learned from its past mistakes by offering a more conservative guidance. The analyst also believes that AxoGen could become an M&A target since its potential acquirers have improved leverage ratios and have discussed deploying capital. Moreover, Zimmerman anticipates AxoGen's Avance nerve graft platform to be granted a Biologics License Application status by the FDA, but even in its absence, the analyst contends the company "isn't limited from selling Avance under 361 HCT/P," or Human cells, tissues, or cellular or tissue-based products regulations.

AXGN AxoGen
$20.44

-1.74 (-7.84%)

10/30/18
JEFF
10/30/18
NO CHANGE
Target $45
JEFF
Buy
AxoGen remains a top growth idea at Jefferies
Jefferies analyst Raj Denhoy says that after a couple of "choppy quarters," AxoGen posted 41% revenue growth in Q3 and kept 2018 guidance at greater than 40%. The outlook for 2019 was offered up as "at least 35%," which keeps AxoGen among the best medtech growth companies, Denhoy tells investors in a post-earnings research note. He sees an upward bias to 2019 estimates and says the company remains a top growth idea with a Buy rating and $45 price target.
11/14/18
BTIG
11/14/18
INITIATION
BTIG
Neutral
AxoGen initiated with a Neutral at BTIG
BTIG analyst Ryan Zimmerman initiated AxoGen with a Neutral rating, saying that while the company has been "one of the best growth stories in small-cap MedTech", its valuation appears to be fair. The analyst is positive on the company's peripheral nerve repair products which, as he claims, show "superiority against the standard of care". Zimmerman also points to AxoGen's market opportunity in breast, pain, and oral/maxillofacial surgery areas that imply a runway for AxoGen's future revenue growth.
12/19/18
JEFF
12/19/18
NO CHANGE
Target $45
JEFF
Buy
Jefferies disagrees 'on all accounts' with short seller report on AxoGen
AxoGen shares were down 25% yesterday following publication of a short report by Seligman Investments, noted Raj Denhoy. While a point-by-point refutation is not really feasible to a 114 page long report, he disagrees "on all accounts" with the short's claims that AxoGen's products are not differentiated, that the markets for its products are smaller and that the company is worth just a fraction of the stock's current valuation, Denhoy tells investors. Market size has always been a point of debate at AxoGen, but the analyst's work shows that its markets are "far more substantial" than the short seller claims. Additionally, no other company he is aware of is working on bringing a processed nerve allograft to the U.S. market, Denhoy said. He maintains a Buy rating and $45 price target on AxoGen shares.
12/19/18
JMPS
12/19/18
NO CHANGE
JMPS
Outperform
JMP says short's suggestion of AxoGen saturation inconsistent with performance
After Seligman Investments distributed a "lengthy" short report on AxoGen that contributed to the stock declining by about 22% yesterday, JMP Securities analyst David Turkaly said he views the three most meaningful remarks as raising potential concerns over the company's previously stated addressable market size, portfolio of intellectual property and current market valuation. However, he believes AxoGen's sales growth, increased rep hiring, active account additions and guidance show that the market saturation suggested by the short report author is inconsistent with recent performance. The short also touched on the regulatory status of Avance, but Turkaly believes AxoGen has been taking adequate steps to successfully progress through its clinical pathway and "constructively communicate" with the FDA, the analyst added. He maintains an Outperform rating and $43 price target on AxoGen shares.

TODAY'S FREE FLY STORIES

NCBS

Nicolet Bankshares

$71.67

-0.02 (-0.03%)

16:09
01/21/20
01/21
16:09
01/21/20
16:09
Earnings
Nicolet Bankshares reports Q4 EPS $1.18, consensus $1.13 »

Reports Q4 provision for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VMW

VMware

$148.76

-2.52 (-1.67%)

16:08
01/21/20
01/21
16:08
01/21/20
16:08
Hot Stocks
VMware acquires Nyansa »

VMware announced its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JOE

Saint Joe Co.

$20.83

0.41 (2.01%)

16:08
01/21/20
01/21
16:08
01/21/20
16:08
Hot Stocks
Saint Joe Co., Flournoy Development announces JV over Panama City community »

The St. Joe Company…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

COF

Capital One

$102.37

-1.77 (-1.70%)

16:08
01/21/20
01/21
16:08
01/21/20
16:08
Hot Stocks
Capital One reports Q4 net charge-offs of $1.7B »

Q4 provision for credit…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Jan

  • 21

    Jan

  • 26

    Feb

ADPT

Adaptive Biotechnologies

$26.75

-1.32 (-4.70%)

16:07
01/21/20
01/21
16:07
01/21/20
16:07
Earnings
Adaptive Biotechnologies sees FY19 revenue $84M - $85M, consensus $82.76M »

Preliminary and unaudited…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NFLX

Netflix

$339.25

-0.31 (-0.09%)

16:07
01/21/20
01/21
16:07
01/21/20
16:07
Hot Stocks
Netflix down 2.5% after Q4 earnings, Q1 guidance »

In after-hours trading,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Jan

PROF

Profound Medical

$12.50

-0.47 (-3.62%)

16:07
01/21/20
01/21
16:07
01/21/20
16:07
Syndicate
Profound Medical files to sell common stock, no amount given »

Cowen is acting as the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IBM

IBM

$138.96

0.65 (0.47%)

16:07
01/21/20
01/21
16:07
01/21/20
16:07
Earnings
IBM reports Q4 cloud & cognitive software revenue $7.2B, up 8.7% »

Reports Q4 Global…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Jan

  • 22

    Jan

CTT

CatchMark Timber

$11.13

-0.1 (-0.89%)

16:07
01/21/20
01/21
16:07
01/21/20
16:07
Hot Stocks
CatchMark Timber appoints Brian Davis as CEO »

CatchMark Timber Trust…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ORRF

Orrstown Financial

$22.48

(0.00%)

16:07
01/21/20
01/21
16:07
01/21/20
16:07
Hot Stocks
Orrstown Financial increases quarterly dividend 13.3% »

The board declared a cash…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

COF

Capital One

$102.34

-1.8 (-1.73%)

16:06
01/21/20
01/21
16:06
01/21/20
16:06
Hot Stocks
Breaking Hot Stocks news story on Capital One »

Capital One reports Q4…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Jan

  • 21

    Jan

  • 26

    Feb

NFLX

Netflix

$339.02

-0.54 (-0.16%)

16:06
01/21/20
01/21
16:06
01/21/20
16:06
Hot Stocks
Netflix sees 2019 as peak for annual free cash flow deficit »

Netflix said: "In…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Jan

ORRF

Orrstown Financial

$22.48

(0.00%)

16:06
01/21/20
01/21
16:06
01/21/20
16:06
Earnings
Orrstown Financial reports Q4 diluted EPS 38c, consensus 44c »

Reports 23% growth in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IBM

IBM

$138.92

0.61 (0.44%)

16:06
01/21/20
01/21
16:06
01/21/20
16:06
Earnings
IBM sees FY20 adjusted EPS of 'at least' $13.35, consensus $13.29 »

The company expects GAAP…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Jan

  • 22

    Jan

COF

Capital One

$102.41

-1.73 (-1.66%)

16:05
01/21/20
01/21
16:05
01/21/20
16:05
Earnings
Capital One reports Q4 adjusted EPS $2.49, consensus $2.28 »

Reports Q4 revenue $7.4B,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Jan

  • 21

    Jan

  • 26

    Feb

IBM

IBM

$138.94

0.63 (0.46%)

16:05
01/21/20
01/21
16:05
01/21/20
16:05
Earnings
IBM reports Q4 adjusted EPS $4.71, consensus $4.68 »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Jan

  • 22

    Jan

NFLX

Netflix

$339.66

0.1 (0.03%)

, DIS

Disney

$143.32

-0.93 (-0.64%)

16:05
01/21/20
01/21
16:05
01/21/20
16:05
Hot Stocks
Netflix says "We have a big headstart in streaming" »

Regarding competition,…

NFLX

Netflix

$339.66

0.1 (0.03%)

DIS

Disney

$143.32

-0.93 (-0.64%)

AAPL

Apple

$316.41

-2.25 (-0.71%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Jan

  • 28

    Jan

  • 04

    Feb

IBKR

Interactive Brokers

$50.99

0.8 (1.59%)

16:04
01/21/20
01/21
16:04
01/21/20
16:04
Hot Stocks
Interactive Brokers reports Q4 total DARTs down 16% at 797K »

Q4 customer equity grew…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Jan

SFBS

ServisFirst

$36.31

-0.61 (-1.65%)

16:03
01/21/20
01/21
16:03
01/21/20
16:03
Hot Stocks
ServisFirst increases quarterly dividend 17% »

ServisFirst increased its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Jan

INTC

Intel

$60.67

1.09 (1.83%)

16:03
01/21/20
01/21
16:03
01/21/20
16:03
Hot Stocks
Intel board chair Andy Bryant to step down »

Intel Corporation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

NFLX

Netflix

$339.05

-0.51 (-0.15%)

16:03
01/21/20
01/21
16:03
01/21/20
16:03
Hot Stocks
Netflix targeting 16% operating margin in 2020 »

Netflix said in its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Jan

AMTD

TD Ameritrade

$51.04

0.53 (1.05%)

16:02
01/21/20
01/21
16:02
01/21/20
16:02
Earnings
TD Ameritrade reports Q1 net new client assets $29B, up 9% y/y »

Reports Q1 average client…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SFBS

ServisFirst

$36.34

-0.58 (-1.57%)

16:02
01/21/20
01/21
16:02
01/21/20
16:02
Earnings
ServisFirst reports Q4 diluted EPS 76c, consensus 69c »

Net interest margin…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Jan

SIBN

SI-Bone

$22.00

0.13 (0.59%)

16:02
01/21/20
01/21
16:02
01/21/20
16:02
Syndicate
SI-Bone fiels to sell 4.3M in common stock »

Morgan Stanley and BofA…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IBKR

Interactive Brokers

$50.98

0.79 (1.57%)

16:02
01/21/20
01/21
16:02
01/21/20
16:02
Earnings
Interactive Brokers reports Q4 EPS 58c, consensus 61c »

Reports Q4 net revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Jan

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.